Dosing Begins in Phase 3 PHOENIX Trial of AMX0035
Amylyx Pharmaceuticals‘ global Phase 3 clinical trial investigating AMX0035 as an oral treatment for amyotrophic lateral sclerosis (ALS) has begun…
Articles by Patricia Inácio, PhD
AC Immune, UPenn Extending Work Into TDP-43 Protein’s Role in ALS
AC Immune has extended its research collaboration with scientists at the University of Pennsylvania (UPenn) working to uncover how…
Preclinical Data Support GeNeuro Antibody for Treating Sporadic ALS
New early clinical study results support the potential of GN-K01, an investigational antibody being developed by GeNeuro, as a…
Dec. 7 is Deadline for Medicare Open Enrollment
The ALS Association is reminding amyotrophic lateral sclerosis (ALS) patients and caregivers that the open enrollment period for Medicare…
Global Enrollment Starts for Phase 3b Trial of Oral Edaravone
Note: This story was updated Oct. 19, 2021, to note that the trial is taking place at 90 clinical…
Amgen, Neumora Partner to Develop Precision Therapies for ALS
Amgen and Neumora Therapeutics announced that they are collaborating to develop precision therapies for amyotrophic lateral sclerosis…
Simultaneous Spinal, Blood Infusions of MSCs May Delay ALS Progression
Simultaneous injections of mesenchymal stem cells (MSCs) into the blood and spinal canal were found to delay disease progression…
$80M Funding Will Help Expansion Develop RNA-targeted Therapies
Expansion Therapeutics has raised $80 million in funding to support the development of its small molecule RNA platform, called…
Gene Therapy Program for ALS Due to C9orf72 Mutations Opening in UK
Research into gene therapies for motor neuron diseases (MNDs), a group of progressive neurological disorders that includes amyotrophic lateral sclerosis,…
ALS Association Offering Doctors ‘thinkALS’ Guide to Speed Diagnosis
The ALS Association has launched a new diagnostic guide — called thinkALS — to aid neurologists in more quickly…